Search

Displaying results 4871 - 4880 of 10000 in total
  1. Drug

    Dimethylcurcumin

    go.drugbank.com/drugs/DB06133
    Investigational

    Dimethylcurcumin is a synthetic chemical compound that is loosely based on a compound found in curcumin. It is a novel anti-androgen that enhances androgen receptor degradation.

  2. Drug

    Mocetinostat

    go.drugbank.com/drugs/DB11830
    Investigational

    Mocetinostat has been used in trials studying the treatment of Lymphoma, Urothelial Carcinoma, Relapsed and Refractory, Myelodysplastic Syndrome, and Metastatic Leiomyosarcoma, among others.

  3. Drug

    7-Nitroindazole

    go.drugbank.com/drugs/DB02207
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    GW 468816

    go.drugbank.com/drugs/DB05417
    Investigational

    GW 468816 is glycine receptor antagonist. It is designed to aid abstinence in people who have just quit smoking, delaying the time to relapse. It was undergoing phase II trials since December 2003.

    Categories: Receptors, N-Methyl-D-Aspartate, antagonists & inhibitors
  5. Drug

    Interferon gamma-1b

    go.drugbank.com/drugs/DB00033
    ApprovedInvestigational

    Purification of the product is achieved by conventional column chromatography. … The sequence displayed is a cDNA sequence which codes for human interferon gamma, as described by Gray et. al. and not specifically interferon gamma 1b.

    Synonyms: IFN-gamma 1b, IFN-gamma-1b
  6. Drug

    OBE101

    go.drugbank.com/drugs/DB05080
    Experimental

    OBE101 is a new weight loss drug developed by Obecure Ltd. It is a new formulation that is based on the vertigo medication, Betahistine. … Obecure is repurposing betahistine, which is an H1 receptor agonist and partial H3 receptor antagonist for the treatment of obese individuals and for other weight management indications.

  7. Drug

    CPD 923

    go.drugbank.com/drugs/DB05856
    Experimental

    CPD 923 (N-butylgalactonorjirimycin) is an iminosugar and an analogue of ZavescaTM. It shows efficacy in vivo studies, as well as a favourable pre-clinical tolerability profile.

  8. Drug

    Perospirone

    go.drugbank.com/drugs/DB08922
    Investigational

    Dainippon Sumitomo Pharma developed perospirone in Japan in 2001 for the treatment of acute schizophrenia and bipolar mania as well as chronic schizophrenia. … Classified as a neuroleptic agent, perospirone is shown to be effective against positive, negative and general symptoms in patients with schizophrenia [A19676].

    Synonyms: cis-N-(4-(4-(1,2-Benzisothiazol-3-yl)-1-piperazinyl)butyl)-1,2-cyclohexanedicarboximide
  9. Drug

    Ethyl pyruvate

    go.drugbank.com/drugs/DB05869
    Investigational

    CTI-01 shows a potent anti-inflammatory and tissue protection activity in multiple animal models of disease including pancreatitis, ischemia-reperfusion injury, sepsis, renal injury and endotoxemia. … CTI-01 (ethyl pyruvate) is a novel anti-inflammatory agent for the treatment of critical inflammatory conditions.

  10. Drug

    Omarigliptin

    go.drugbank.com/drugs/DB11992
    Investigational

    Omarigliptin has been used in trials studying the treatment of Type 2 Diabetes Mellitus and Chronic Renal Insufficiency.

    Categories: DPP-IV Inhibitors